To sum up, these results suggested that by targeting the miR-27a-3p/Hoxa10/Kv4.3 axis could effectively inhibit the process of myocardial hypertrophy and cardiomyocyte hypertrophy, which provided us a new therapeutic strategy for myocardial hypertrophy and electrical remodeling. The gene discussed is HOXA10; the disease is cardiac hypertrophy.